CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
FibroTarg focuses on developing Fibrolisine, a novel anti-fibrotic drug candidate aimed at treating chronic kidney disease by halting fibrosis progression. The project evaluates its effectiveness in advanced kidney models and explores its commercial viability.
Chronic kidney disease (CKD) is a progressive disease that is prevalent in 10% of the developed world and develops as a result of diabetes mellitus, hypertension, glomerulonephritis or acute kidney injury.
Over time, CKD can progress to end-stage renal disease (ESRD); a condition that can only be treated through hemodialysis or kidney transplantation, posing a severe medical, societal and economic challenge.
Fibrosis is recognized as a key pathological mechanism in CKD, responsible for slowly de…
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
